Citicoline (Ceraxon) in acute stroke: assessment of clinical efficacy and effects on cerebral perfusion

Citicoline (Ceraxon) in acute stroke: assessment of clinical efficacy and effects on cerebral perfusion

Blog Article

Novel neuroimaging techniques iphone 11 price edmonton provide quantitative assessmentof cerebral perfusion in acute stroke and reveal the heterogeneityof ischemic zone.Neuroprotective agents playmajor role in the treatment of acute stroke as they are intendedto restore functioning of potentially viable tissue.Thisprospective open-label study included 50 patients (mean age60.9 years) with acute hemispheric stroke within the first 24hours of symptoms onset.

Patients were divided into 2 arms (25patients in each arm) to receive standard of care (control arm)or standard of care plus citicoline (Ceraxon) 1 g b.i.d.as I.

V.injection for 10 days.Clinical symptoms were assessed withNIHSS; neuroimaging included DWI to confirm ischemiclesion and perfusion CT to assess cerebral perfusion.Patientsin both arms demonstrated significant clinical improvement onDay 10 with no significant difference between treatment arms(mean NIHSS score was 9.

4 in control arm and 8.4 in Ceraxonarm, p=0.87).Perfusion CT on admission showed perfusiondeficit in all patients.

Mismatch regions on perfusion CT comparedto DWI indicating potentially viable tissue (penumbra)were found in 75% of patients in control arm and in 69%of patients in Ceraxon arm.No difference between perfusionparameters in the core vs.penumbra on initial imagingwas shown.On Day 10 there were no changes of cerebral perfusionvalues in the core regions, while in penumbra inCeraxon arm CBF increased significantly CBF (p=0.

013) withno significant differences vs.intact hemisphere, that is consistentwith cerebral perfusion improvement.Thus, treatmentwith Ceraxon in the first 10 days of acute stroke glitter foam vellen action may result inimprovement of cerebral perfusion in the potentially viable tissue.